Autologous CD30+ CAR T Cells therapy(New York Medical College)

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug NameAutologous CD30+ CAR T Cells therapy(New York Medical College)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived
Mechanisms of ActionT lymphocyte replacementsTumor necrosis factor receptor superfamily member 8 modulators
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsHodgkin Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNew York Medical CollegeUniversity Of North Carolina At Chapel Hill
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of North Carolina At Chapel HillNew York Medical College
Inactive CompaniesN/A
Active IndicationsHodgkin Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A